Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 13.73% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -10.53
2
Risky -
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CAD 30 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.07
-67.85%
11.68
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.0%
0%
-36.0%
6 Months
-31.43%
0%
-31.43%
1 Year
2.13%
0%
2.13%
2 Years
-22.58%
0%
-22.58%
3 Years
4.35%
0%
4.35%
4 Years
-77.57%
0%
-77.57%
5 Years
-84.0%
0%
-84.0%
Avicanna, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
91.81%
EBIT Growth (5y)
13.73%
EBIT to Interest (avg)
-10.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
9.37
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.76
EV to EBIT
-14.18
EV to EBITDA
-21.72
EV to Capital Employed
13.60
EV to Sales
1.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-95.90%
ROE (Latest)
-67.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
6.20
6.30
-1.59%
Operating Profit (PBDIT) excl Other Income
-0.50
0.20
-350.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-0.70
0.10
-800.00%
Operating Profit Margin (Excl OI)
-115.70%
4.50%
-12.02%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.59% vs -4.55% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -800.00% vs 0.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
25.50
16.80
51.79%
Operating Profit (PBDIT) excl Other Income
-3.10
-6.90
55.07%
Interest
0.30
0.60
-50.00%
Exceptional Items
0.10
-0.60
116.67%
Consolidate Net Profit
-3.60
-8.70
58.62%
Operating Profit Margin (Excl OI)
-155.60%
-457.30%
30.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 51.79% vs 320.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 58.62% vs 40.82% in Dec 2023
About Avicanna, Inc. 
Avicanna, Inc.
Pharmaceuticals & Biotechnology
Avicanna Inc. is a Canada-based biopharmaceutical company. The Company is focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments. In addition to its developing pharmaceutical pipeline, it has product lines, including Pura H&W and RHO Phyto. Pura H&W is a line of cannabidiol (CBD) consumer derma-cosmetic products. RHO Phyto is a line of medical cannabis products containing varying ratios of CBD and tetrahydrocannabinol (THC). The Company's subsidiary includes Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S.
Company Coordinates 
Company Details
480 UNIVERSITY AVENUE, SUITE 1502 , TORONTO ON : M5G 1V2
Registrar Details






